{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:33:57Z","timestamp":1789209237669,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,12,18]],"date-time":"2011-12-18T00:00:00Z","timestamp":1324166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> In irritable bowel syndrome (IBS) subtyping is used in research and clinical practice. Knowledge of subtype stability is needed for proper design of trials and treatment strategies.<\/jats:p><jats:p><jats:bold>Aims\u2002<\/jats:bold> To evaluate the stability of Rome III IBS subtypes over time and to determine the optimal time period for prospective, diary\u2010based subtyping.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Rome III IBS patients aged 18\u201370\u2003years enrolled in two identical, randomised, placebo\u2010controlled trials of probiotics, were included. No difference was found on stool pattern, thus patients were analysed as one group. Patients scored defaecations according to Bristol Stool Form Scale for 10\u2003weeks. IBS subtypes were determined for all 1\u2010 and 2\u2010week periods. Subtype distribution and stool pattern over time were determined. The proportions of patients having the same subtype all weeks (stable patients) or having a predominant subtype (same subtype \u226560% of time) were determined.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A total of 126 patients, mean age 46\u2003\u00b1\u200315\u2003years, 72% women were included. Subtype distribution was similar over time with IBS with constipation, IBS with diarrhoea and IBS unsubtyped constituting one\u2010third of the population each. Even though only 18\u201335% had the same subtype all weeks, the majority of patients had the same subtype for \u226560% of time (82\u201398%). Sixty\u2010nine per cent had the same predominant and baseline subtypes. Two\u2010week data increased the proportion of stable patients, of patients with a predominant subtype, and of patients who had similar baseline and predominant subtype.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Most IBS patients change subtype over time. However, an underlying stool pattern stability was demonstrated in the majority of patients. To increase stability, we recommend 2\u2010week data for IBS subtyping.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2011.04948.x","type":"journal-article","created":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T01:51:41Z","timestamp":1324259501000},"page":"350-359","source":"Crossref","is-referenced-by-count":55,"title":["Short\u2010term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification"],"prefix":"10.1111","volume":"35","author":[{"given":"A. L.","family":"Engsbro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Simren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bytzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-009-0039-x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.12.006"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6722.439"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04322.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01441.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","unstructured":"LewisSJ.Stool form scale as a useful guide to intestinal transit time.1997.","DOI":"10.3109\/00365529709011203"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37095b"},{"issue":"1","key":"e_1_2_6_10_2","first-page":"S1","article-title":"An evidence\u2010based position statement on the management of irritable bowel syndrome","volume":"104","author":"Brandt LJ","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0801447"},{"key":"e_1_2_6_12_2","unstructured":"QuigleyE FriedM GweeKA et\u00a0al.WGO Practice Guideline \u2013 irritable bowel syndrome: a global perspective. Available at:http:\/\/www.worldgastroenterology.org. 2009. Accessed July 25 2011."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.119446"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.69"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.meg.0000252641.64656.41"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04183.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2011.565066"},{"key":"e_1_2_6_18_2","first-page":"351","volume-title":"Rome II: The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment. A Multinational Consensus","author":"Thompson WG","year":"2000"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7441.702"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2008.04.004"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.12.006"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.06.010"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40674.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03197.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31815bd749"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02723.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1572-0241.2003.04023.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41211.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04328.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04948.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2011.04948.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:45:01Z","timestamp":1698738301000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04948.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,18]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1365-2036.2011.04948.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04948.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,18]]}}}